Fort Washington Investment Advisors Inc. OH Boosts Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Fort Washington Investment Advisors Inc. OH lifted its stake in Johnson & Johnson (NYSE:JNJ) by 4.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,702,574 shares of the company’s stock after buying an additional 67,629 shares during the period. Johnson & Johnson makes up approximately 1.5% of Fort Washington Investment Advisors Inc. OH’s holdings, making the stock its 15th largest holding. Fort Washington Investment Advisors Inc. OH owned about 0.07% of Johnson & Johnson worth $246,226,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the stock. Vinva Investment Management Ltd lifted its position in shares of Johnson & Johnson by 6.8% in the 3rd quarter. Vinva Investment Management Ltd now owns 111,448 shares of the company’s stock worth $17,988,000 after purchasing an additional 7,110 shares during the period. Financial Counselors Inc. boosted its position in Johnson & Johnson by 5.3% during the 3rd quarter. Financial Counselors Inc. now owns 185,093 shares of the company’s stock valued at $29,996,000 after acquiring an additional 9,309 shares in the last quarter. Meridian Investment Counsel Inc. grew its holdings in shares of Johnson & Johnson by 19.6% during the 3rd quarter. Meridian Investment Counsel Inc. now owns 22,629 shares of the company’s stock worth $3,667,000 after acquiring an additional 3,710 shares during the period. Charles Schwab Investment Management Inc. raised its position in shares of Johnson & Johnson by 0.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 17,639,368 shares of the company’s stock worth $2,858,543,000 after acquiring an additional 102,502 shares in the last quarter. Finally, Lord Abbett & CO. LLC purchased a new position in shares of Johnson & Johnson in the 3rd quarter valued at approximately $69,859,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. StockNews.com downgraded Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Friday, January 17th. Morgan Stanley dropped their price objective on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a research note on Thursday. Barclays lowered their target price on shares of Johnson & Johnson from $160.00 to $159.00 and set an “equal weight” rating for the company in a report on Tuesday. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Finally, Citigroup dropped their target price on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. Nine investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average price target of $170.06.

Insider Buying and Selling

In related news, Director Mark A. Weinberger purchased 1,000 shares of Johnson & Johnson stock in a transaction on Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the transaction, the director now directly owns 1,000 shares in the company, valued at $147,220. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.16% of the stock is owned by insiders.

Johnson & Johnson Stock Performance

JNJ stock opened at $146.58 on Friday. The company has a market cap of $352.91 billion, a P/E ratio of 21.21, a price-to-earnings-growth ratio of 2.52 and a beta of 0.51. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85. The stock’s fifty day moving average price is $148.10 and its 200-day moving average price is $156.05.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.99 by $0.05. The firm had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22,438,500 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The business’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.29 EPS. On average, equities analysts forecast that Johnson & Johnson will post 9.95 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.38%. Johnson & Johnson’s dividend payout ratio (DPR) is 71.78%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.